title: [Adverse effects of lithium treatment and safety routines].
abstract: Successful lithium treatment of manic disorders was reported in 1949 by John Cade. This marked the beginning of the pharmacological era in psychiatry. In spite of the emergence of alternative drugs with antimanic and moodstabilising properties, lithium remains the primary long-term treatment for preventing relapse of bipolar disorders. Among the adverse effects of lithium treatment are unintentional lithium intoxication, nephropathy, hypothyroidism, hypercalcemia, hyperparathyroidism, diarrhoea, tremor, weight gain, and effects on the fetus and the newborn child. Early detection or prevention of adverse effects, particularly lithium intoxication, is vital for safety. Therefore, P-lithium and P-creatinine are assessed every 4 months (and pre-lithium) while thyroid and parathyroid function, weight, 24 h consumption of liquids (or 24 h urinary output), B-glucose, and blood pressure are assessed annually (and pre-lithium). Urinary concentrating capacity and glomerular filtration rate are always measured after 5 years of lithium treatment, and always when clinically indicated. Patient education and annual reinforcement of his/her knowledge of pertinent aspects of the treatment and of risk factors for lithium intoxication are important aspects for ensuring safety.
authors.affiliation: Universitetssjukhuset i Lund. hans.bendz@skane.se
authors.forename: Hans
authors.initials: H
authors.lastname: Bendz
authors.forename: Mattias
authors.initials: M
authors.lastname: Aurell
mesh_terms: D001714:Bipolar Disorder / Q000188:drug therapy*; D006801:Humans; D007677:Kidney Function Tests; D008094:Lithium / Q000008:administration & dosage / Q000009:adverse effects* / Q000506:poisoning; D009399:Nephrons / Q000187:drug effects; D010280:Parathyroid Glands / Q000187:drug effects; D012307:Risk Factors; D012449:Safety; D013960:Thyroid Function Tests
chemical_list: D008094:Lithium